Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Induction therapy for active lupus nephritis: mycophenolate mofetil is superior to cyclophosphamide

Nature Clinical Practice Rheumatology volume 2, pages 354–355 (2006)Cite this article

boxed-textGinzler EM et al. (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353: 2219–2228

Mycophenolate mofetil is an effective and well-tolerated alternative to cyclophosphamide in the treatment of patients with lupus nephritis

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Austin HA III et al. (1986) Therapy of lupus nephritis: controlled trial of prednisone and cytoxic drugs. N Engl J Med 314: 614–619

    Article  Google Scholar 

  2. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group (1996) A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantion. Transplantation 61: 1029–1037

  3. Karim MY et al. (2002) Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressant agents. Rheumatology 41: 876–882

    Article  CAS  Google Scholar 

  4. Chan TM et al. (2005) Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 16: 1076–1084

    Article  CAS  Google Scholar 

  5. Pisoni CN et al. (2005) Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol 32: 1047–1052

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Chloe Harman, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Associate Professor of Medicine and Epidemiology and co-Director of the Lupus Center of Excellence,

    Jennifer R Elliott & Susan Manzi

  2. Research Fellow in Rheumatology, at the University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

    Jennifer R Elliott & Susan Manzi

Authors
  1. Jennifer R Elliott
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan Manzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susan Manzi.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Elliott, J., Manzi, S. Induction therapy for active lupus nephritis: mycophenolate mofetil is superior to cyclophosphamide. Nat Rev Rheumatol 2, 354–355 (2006). https://doi.org/10.1038/ncprheum0217

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncprheum0217

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing